Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Shangbay Capital

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 28
Average round size
info
The average size of a deal this fund participated in
$23M
Portfolio companies 25
Rounds per year 3.50
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 2
Key employees 3

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Medical
  • Therapeutics
Summary

The leading representative office of defined VC is situated in the Palo Alto. The venture was found in North America in United States.

Among the most successful fund investment fields, there are Genetics, Biopharma. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Berkeley Lights, Lucira Health, Emboline. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Speaking about the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2018. The fund is constantly included in 2-6 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars.

Besides them, we counted 3 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Shangbay Capital, startups are often financed by Y Combinator, Medvance Incubator Partners, Data Collective DCVC. The meaningful sponsors for the fund in investment in the same round are WuXi Healthcare Ventures, SV Tech Ventures, Aethan Capital. In the next rounds fund is usually obtained by WuXi Healthcare Ventures, Sequoia Capital China, Sangel Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Shangbay Capital:
Typical Co-investors
Shangbay Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Shangbay Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Decide4action Greenville, South Carolina, United States
Digital Disrupt -
GMH Ventures Newtown Square, Pennsylvania, United States
Guosheng Financial Holding Inc China, Foshan, Guangdong
Haitong Kaiyuan Investment China, Shanghai
Hersh Interactive Group -
Korea Credit Guarantee Fund Daegu, South Korea, Taegu-jikhalsi
Loudwater Investment Partners England, London, United Kingdom
Mechanics Bank California, Richmond, United States
Million Tons Capital China, Shanghai
Mindset Ventures Brazil, São Paulo, Sao Paulo
Ningbo Dianshangcheng Investment Development China, Ningbo, Zhejiang
Patriot Capital Funding Connecticut, United States, Westport
POD Holding Boston, Massachusetts, United States
Ranwa Technologies Co. -
SternAegis Ventures New York, New York, United States
Taiwan Tech Arena -
Venture One New York, New York, United States
XFactor Ventures Boston, Massachusetts, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Telesair

Health Care
Hospital
Personal Health
$22M10 Jan 2023 Irvine, California, United States

Luminopia

Commercial
Computer Vision
Industrial
Software
Virtual Reality
$5M11 Nov 2022 Cambridge, Massachusetts, United States

Contraline

Biotechnology
Drug Discovery
Health Care
Medical Device
Pharmaceuticals
$7M10 Nov 2022 Virginia, United States

Huma.ai

Artificial Intelligence
Health Care
$9M07 Feb 2022 Los Altos, California, United States

Contraline

Biotechnology
Drug Discovery
Health Care
Medical Device
Pharmaceuticals
$10M20 Oct 2021 Virginia, United States

Laplace Interventional

Health Care
Medical Device
$7M01 Sep 2021 Plymouth, Minnesota, United States

Fluid Biotech

Health Care
Medical
Medical Device
$4M11 Aug 2021 Calgary, Canada

Neuro42

Medical Device
$6M27 Jul 2021 Oakland, California, United States

Emboline

Cosmetic Surgery
Health Care
Medical Device
$55M25 May 2021 California, United States
News
Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology

– Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors.
– The $7.9M Series A financing round will fund Laplace Interventional towards achieving its preclinical milestones.
– The company also announced the addition of two Directors to its Board including William Dai, Founding Managing Partner at ShangBay Capital.
– Laplace Interventional’s device aims to offer an increase in life expectancy and an improvement to the quality of life to several patients worldwide diagnosed with Tricuspid Regurgitation (TR).

Fluid Biotech Raises $4.7MUSD in Seed Funding

– Fluid Biotech Inc. from Calgary, AB, Canada closed a $4.7m seed funding round.
– The round was led by Metis Innovative of Miami and ShangBay Capital of Palo Alto, California, with participation from new investors UCeed Health Fund and UCeed Child Health and Wellness Fund from the University of Calgary, Thin Air Labs, Wharton Alumni Angels, Amino Capital, Bluesky Equities, ThresholdImpact and Alabaster Capital.
– The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Shangbay Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: